menu
    • menu

    Company profile for Idera Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. We are devel...
    Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. We are developing our toll-like receptor agonist, tilsotolimod (IMO-2125) to treat certain solid tumors such as melanoma. We aim to dramatically improve the outcomes for patients suffering from these cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Idera PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Pennsylvania 505 Eagleview Boulevard Suite 212 Exton, PA 19341
    Telephone
    Telephone
    484-348-1600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.iderapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/idera-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/iderapharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Idera Announces Name Change to Aceragen & Provides Near-Term Strategic Outlook
    Idera Announces Name Change to Aceragen & Provides Near-Term Strategic Outlook

    17 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/17/2589914/33448/en/Idera-Pharmaceuticals-Announces-Name-Change-to-Aceragen-Inc-and-Provides-Near-Term-Strategic-Outlook.html

    GLOBENEWSWIRE
    17 Jan 2023
    Share Share
    Aeterna discontinues vaccine development; Idera rebrands as Aceragen
    Aeterna discontinues vaccine development; Idera rebrands as Aceragen

    17 Jan 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/aeterna-discontinues-vaccine-development-idera-rebrands-as-aceragen/

    Paul Schloesser ENDPTS
    17 Jan 2023
    Share Share
    Idera Pharma Reports 3Q 2022 Financial Results and Provides Corporate Update
    Idera Pharma Reports 3Q 2022 Financial Results and Provides Corporate Update

    14 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/14/2555472/33448/en/Idera-Pharmaceuticals-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    14 Nov 2022
    Share Share
    Idera buys rare-disease-focused Aceragen in all-stock deal
    Idera buys rare-disease-focused Aceragen in all-stock deal

    30 Sep 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/good-idera-pharma-buys-rare-disease-focused-aceragen-all-stock-deal-keep-money-flowing

    James Waldron FIERCEBIOTECH
    30 Sep 2022
    Share Share
    Idera Pharmaceuticals Acquires Aceragen
    Idera Pharmaceuticals Acquires Aceragen

    28 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/28/2524718/0/en/Idera-Pharmaceuticals-Acquires-Aceragen.html

    GLOBENEWSWIRE
    28 Sep 2022
    Share Share
    Idera Stops Enrollment in Phase 2 Melanoma Trial Following Positive Early Data
    Idera Stops Enrollment in Phase 2 Melanoma Trial Following Positive Early Data

    19 May 2022

    // TRIALSITENEWS

    https://www.trialsitenews.com/a/idera-stops-enrollment-in-phase-2-melanoma-trial-following-positive-early-data-29368cae

    TRIALSITENEWS
    19 May 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search